Question

Which of the following statements is incorrect regarding Gilenya (fingolimod)?

a. First dose observation is required to monitor heart rate, BP, and EKG for 6 hours
following dose
b. Patients should have their eyes examined prior to and 3‐4 months after initiating
treatment due to risk of macular edema
c. Patient should be educated on the symptoms of Progressive Multifocal
Leukoencephalopathy (PML) prior to initiating therapy
d. It isn't necessary to repeat first dose observation if a patient has missed 2 weeks of
Gilenya

Answer 1

The incorrect statement about Gilenya is that first dose observation does not need to be repeated if a patient misses 2 weeks of treatment. In fact, this observation must be repeated to ensure safety.

Step-by-step explanation:

The statement that is incorrect regarding Gilenya (fingolimod) is 'It isn't necessary to repeat first dose observation if a patient has missed 2 weeks of Gilenya.' On the contrary, if a patient miss taking Gilenya for 2 weeks or more, they should undergo the entire first dose observation process again. This includes monitoring of heart rate, blood pressure (BP), and an EKG for 6 hours. Additionally, due to the risk of macular edema, it is recommended that patients have their eyes examined before starting treatment and again 3-4 months after initiating treatment. Patients should also be educated on the symptoms of Progressive Multifocal Leukoencephalopathy (PML) prior to initiating therapy, as it is a serious condition that can occur in those taking Gilenya.